Impacts of CD40- and CD86-Silenced Antigen-Specific B Cells on the Control of Allergies.

CONCLUSION: This study showed, for the first time, that siRNA-induced CD86-silenced B cells significantly inhibited allergic responses and symptoms antigen-specifically, and that siRNA-induced CD40-/CD86-silenced antigen-specific B cells are a more useful antigen-specific therapy than CD40- or CD86-silenced B cells alone for the control of allergies. Furthermore, it was shown that CD40-/CD86-silenced B cells have stronger inhibition of IgE production and allergic symptoms than CD40-/CD86-silenced DCs. PMID: 31064207 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31064207?dopt=Abstract

Source: American Journal of Rhinology and Allergy - May 7, 2019 Category: ENT & OMF Authors: Suzuki M, Matsumoto T, Toyoda K, Nakamura Y, Murakami S Tags: Am J Rhinol Allergy Source Type: research